keyword
MENU ▼
Read by QxMD icon Read
search

Osteosarcoma adult

keyword
https://www.readbyqxmd.com/read/27904684/ldhb-may-be-a-significant-predictor-of-poor-prognosis-in-osteosarcoma
#1
Chao Li, Yu Chen, Pingping Bai, Jiaqiang Wang, Zhenhui Liu, Tao Wang, Qiqing Cai
Osteosarcoma is the most common primary malignant bone tumor in children and young adults. Lactate dehydrogenase (LDH) is considered as the key glycolytic enzyme and involved in tumor initiation and metabolism. Here, we firstly found that LDHB was highly expressed in osteosarcoma cell lines. Expression profiling indicated that LDHB mRNA was elevated in osteosarcoma tissues with metastasis versus without metastasis, and LDHB high expression predicted a poor prognosis in patients. After LDHB knockdown by siRNA transfection, cell growth and proliferation were inhibited and presented a dose-dependent cell death via MTT assay...
2016: American Journal of Translational Research
https://www.readbyqxmd.com/read/27888627/identification-of-differentially-expressed-genes-in-the-development-of-osteosarcoma-using-rna-seq
#2
Yihao Yang, Ya Zhang, Xin Qu, Junfeng Xia, Dongqi Li, Xiaojuan Li, Yu Wang, Zewei He, Su Li, Yonghong Zhou, Lin Xie, Zuozhang Yang
OBJECTIVE: Osteosarcoma (OS) is a malignant bone tumor with high morbidity in young adults and adolescents. This study aimed to discover potential early diagnosis biomarkers in OS. RESULTS: In total, 111 differentially expressed genes (DEGs) were identified in primary OS compared with normal controls and 235 DEGs were identified in metastatic OS compared with primary OS. AURKB and PPP2R2B were the significantly up-regulated and down-regulated hub proteins, respectively, in the PPI protein-protein network (PPI) network of primary OS...
November 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/27885099/rotationplasty-in-adult-cancer-patients-what-is-the-rehab-strategy-and-what-results-can-be-expected-a-case-study
#3
Mattia Morri, Cristiana Forni
BACKGROUND AND AIM: Rotationplasty is an important and demanding challenge for physiotherapists. The aim of this paper is to describe the functional outcome achieved by a patient undergoing rotationplasty in adult age following osteosarcoma. CASE DESCRIPTION AND METHODS: The patient was followed throughout the rehabilitation course and the results achieved were recorded at 6, 9 and 12 months after surgery. FINDINGS AND OUTCOMES: The results progressively improved in terms of function, functional performance and quality of life...
November 24, 2016: Prosthetics and Orthotics International
https://www.readbyqxmd.com/read/27852052/micrornas-for-osteosarcoma-in-the-mouse-a-meta-analysis
#4
REVIEW
Junli Chang, Min Yao, Yimian Li, Dongfeng Zhao, Shaopu Hu, Xuejun Cui, Gang Liu, Qi Shi, Yongjun Wang, Yanping Yang
Osteosarcoma (OS) is the most common primary malignant bone carcinoma with high morbidity that happens mainly in children and young adults. As the key components of gene-regulatory networks, microRNAs (miRNAs) control many critical pathophysiological processes, including initiation and progression of cancers. The objective of this study is to summarize and evaluate the potential of miRNAs as targets for prevention and treatment of OS in mouse models, and to explore the methodological quality of current studies...
November 12, 2016: Oncotarget
https://www.readbyqxmd.com/read/27845066/cinobufagin-induces-apoptosis-of-osteosarcoma-cells-through-inactivation-of-notch-signaling
#5
Yongfei Cao, Ling Yu, Guo Dai, Shanshan Zhang, Zhengpei Zhang, Tian Gao, Weichun Guo
Osteosarcoma (OS) is a major cause of cancer-related mortality in children and young adults worldwide. Due to preexisting or acquired chemoresistance, the current standard neoadjuvant chemotherapy regimens show only moderate activity against OS. In the current study, we explored the potential anti-OS Cinobufagin in vitro and in vivo, and investigated its underlying mechanisms. The antitumor potential of Cinobufagin was assessed using cell viability assays, and cycle and apoptosis were determined. In a cell-based assay, the mRNA and protein expression of Notch-1, Hes-1, Hes-5 and Hey-1 were determined by quantitative polymerase chain reactions and western blotting...
November 12, 2016: European Journal of Pharmacology
https://www.readbyqxmd.com/read/27820947/effect-of-temporal-changes-in-therapeutic-exposure-on-self-reported-health-status-in-childhood-cancer-survivors
#6
Kirsten K Ness, Melissa M Hudson, Kendra E Jones, Wendy Leisenring, Yutaka Yasui, Yan Chen, Marilyn Stovall, Todd M Gibson, Daniel M Green, Joseph P Neglia, Tara O Henderson, Jacqueline Casillas, Jennifer S Ford, Karen E Effinger, Kevin R Krull, Gregory T Armstrong, Leslie L Robison, Kevin C Oeffinger, Paul C Nathan
Background: The effect of temporal changes in cancer therapy on health status among childhood cancer survivors has not been evaluated. Objective: To compare proportions of self-reported adverse health status outcomes among childhood cancer survivors across 3 decades. Design: Cross-sectional. (ClinicalTrials.gov: NCT01120353). Setting: 27 North American institutions. Participants: 14 566 adults, who survived for 5 or more years after initial diagnosis (median age, 27 years; range, 18 to 48 years), treated from 1970 to 1999...
November 8, 2016: Annals of Internal Medicine
https://www.readbyqxmd.com/read/27817080/retraction-note-to-tissue-expression-levels-of-mir-29b-and-mir-422a-in-children-adolescents-and-young-adults-age-groups-and-their-association-with-prediction-of-poor-prognosis-in-human-osteosarcoma
#7
Reza Bahador, Afshin Taheriazam, Alireza Mirghasemi, Ali Torkaman, Mohammadreza Shakeri, Emad Yahaghi, Peyman Karimi Goudarzi
No abstract text is available yet for this article.
November 5, 2016: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/27761754/review-of-osteosarcoma-and-current-management
#8
REVIEW
Ryan A Durfee, Maryam Mohammed, Hue H Luu
Osteosarcoma is the most common primary malignancy of bone in children and young adults. This tumor has a very heterogeneous genetic profile and lacks any consistent unifying event that leads to the pathogenesis of osteosarcoma. In this review, some of the important genetic events involved in osteosarcoma will be highlighted. Additionally, the clinical diagnosis of osteosarcoma will be discussed, as well as contemporary chemotherapeutic and surgical management of this tumor. Finally, the review will discuss some of the novel approaches to treating this disease...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27760307/molecular-genetics-of-osteosarcoma
#9
Kirby Rickel, Fang Fang, Jianning Tao
Osteosarcoma is the predominant form of bone cancer, affecting mostly adolescents. Recent progress made in molecular genetic studies of osteosarcoma has changed our view on the cause of the disease and ongoing therapeutic approaches for patients. As we draw closer to gaining more complete catalogs of candidate cancer driver genes in common forms of cancer, the landscape of somatic mutations in osteosarcoma is emerging from its first phase. In this review, we summarize recent whole genome and/or whole exome genomic studies, and then put these findings in the context of genetic hallmarks of somatic mutations and mutational processes in human osteosarcoma...
October 17, 2016: Bone
https://www.readbyqxmd.com/read/27651797/establishment-and-characterization-of-a-human-small-cell-osteosarcoma-cancer-stem-cell-line-a-new-possible-in-vitro-model-for-discovering-small-cell-osteosarcoma-biology
#10
Gaia Palmini, Roberto Zonefrati, Cecilia Romagnoli, Alessandra Aldinucci, Carmelo Mavilia, Gigliola Leoncini, Alessandro Franchi, Rodolfo Capanna, Maria Luisa Brandi
Osteosarcoma (OSA) is the most common primary malignant bone tumor, usually arising in the long bones of children and young adults. There are different subtypes of OSA, among which we find the conventional OS (also called medullary or central osteosarcoma) which has a high grade of malignancy and an incidence of 80%. There are different subtypes of high grade OS like chondroblastic, fibroblastic, osteoblastic, telangiectatic, and the small cell osteosarcoma (SCO). In this study, for the first time, we have isolated, established, and characterized a cell line of cancer stem cells (CSCs) from a human SCO...
2016: Stem Cells International
https://www.readbyqxmd.com/read/27650817/initial-testing-stage-1-of-the-curaxin-cbl0137-by-the-pediatric-preclinical-testing-program
#11
Richard Lock, Hernan Carol, John M Maris, E Anders Kolb, Richard Gorlick, C Patrick Reynolds, Min H Kang, Stephen T Keir, Jianrong Wu, Andrei Purmal, Andrei Gudkov, Dias Kurmashev, Raushan T Kurmasheva, Peter J Houghton, Malcolm A Smith
BACKGROUND: CBL0137 is a novel drug that modulates FAcilitates Chromatin Transcription (FACT), resulting in simultaneous nuclear factor-κB suppression, heat shock factor 1 suppression and p53 activation. CBL0137 has demonstrated antitumor effects in animal models of several adult cancers and neuroblastoma. PROCEDURES: CBL0137 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro cell line panel at concentrations ranging from 1.0 nM to 10...
September 21, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27633385/drugs-in-early-clinical-development-for-the-treatment-of-osteosarcoma
#12
Marie-Françoise Heymann, Hannah Brown, Dominique Heymann
INTRODUCTION: Osteosarcomas are the main malignant primary bone tumours found in children and young adults. Conventional treatment is based on diagnosis and resection surgery, combined with polychemotherapy. This is a protocol that was established in the 1970s. Unfortunately, this therapeutic approach has reached a plateau of efficacy and the patient survival rate has not improved in the last four decades. New therapeutic approaches are thus required to improve the prognosis for osteosarcoma patients...
September 15, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27605071/progress-and-opportunities-for-immune-therapeutics-in-osteosarcoma
#13
Christina K Lettieri, Nicole Appel, Nicole Labban, Danielle M Lussier, Joseph N Blattman, Pooja Hingorani
Survival outcomes for osteosarcoma have plateaued since the 1980s, and patients with relapsed or refractory disease have a particularly dismal outcome. Treatment options for these patients are limited primarily due to the paucity of effective therapeutics. Immune therapies such as tumor vaccines and traditional antigen-targeted monoclonal antibodies have had limited success in solid tumors. The recent discovery of novel immune checkpoint blockade strategies and their success in adult cancers has revitalized the use of immunotherapy strategies for the treatment of solid tumors...
October 2016: Immunotherapy
https://www.readbyqxmd.com/read/27595362/sarcomas-of-soft-tissue-and-bone
#14
Andrea Ferrari, Uta Dirksen, Stefan Bielack
The definition of soft tissue and bone sarcomas include a large group of several heterogeneous subtypes of mesenchymal origin that may occur at any age. Among the different sarcomas, rhabdomyosarcoma, synovial sarcoma, Ewing sarcoma and osteosarcoma are aggressive high-grade malignancies that often arise in adolescents and young adults. Managing these malignancies in patients in this age bracket poses various clinical problems, also because different therapeutic approaches are sometimes adopted by pediatric and adult oncologists, even though they are dealing with the same condition...
2016: Progress in Tumor Research
https://www.readbyqxmd.com/read/27591503/chemotherapy-does-neoadjuvant-or-adjuvant-therapy-improve-outcomes
#15
REVIEW
Robert J Canter
Since preoperative chemotherapy has been clearly shown to improve outcomes for patients with Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma, practitioners have attempted to extend the use of adjuvant/neoadjuvant chemotherapy to other types of adult soft tissue sarcoma. Given the high risk of distant recurrence and disease-specific death for patients with soft tissue sarcoma tumors larger than 10 cm, these patients should be considered candidates for neoadjuvant chemotherapy as well as investigational therapies...
October 2016: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27554207/primary-lymphoma-of-bone-in-the-pediatric-and-young-adult-population
#16
Karen M Chisholm, Robert S Ohgami, Brent Tan, Robert P Hasserjian, Olga K Weinberg
Primary lymphoma of bone (PLB) accounts for 3-7% of primary neoplasms of bone and must be distinguished from more common bone tumors in the pediatric population such as osteosarcoma, Ewing sarcoma, and other small round blue cell tumors. In this study, pathology databases from four institutions were queried for PLB in individuals 1-21 years old. A total of 54 cases of PLB were identified, including 41 diffuse large B cell lymphomas (DLBCL, 76%), 8 B lymphoblastic lymphomas (BLL, 15%), 3 anaplastic large cell lymphomas (ALCL, 6%), and 2 low grade follicular lymphomas (FL, 4%)...
August 20, 2016: Human Pathology
https://www.readbyqxmd.com/read/27526293/histologic-spectrum-of-giant-cell-tumor-gct-of-bone-in-patients-18-years-of-age-and-below-a-study-of-63-patients
#17
Alyaa Al-Ibraheemi, Carrie Y Inwards, Riyam T Zreik, Doris E Wenger, Sarah M Jenkins, Jodi M Carter, Jennifer M Boland, Peter S Rose, Long Jin, Andre M Oliveira, Karen J Fritchie
Although the majority of giant cell tumors (GCTs) of the bone occur in adult patients, occasionally they arise in the pediatric population. In this setting they may be mistaken for tumors more commonly seen in this age group, including osteosarcoma, aneurysmal bone cyst, and chondroblastoma. All cases of primary GCT of the bone arising in patients 18 years and below were retrieved from our institutional archives and examined with emphasis on the evaluation of various morphologic patterns. Clinical/radiologic records were reviewed when available...
August 11, 2016: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/27507299/impact-of-chemotherapy-on-the-outcome-of-osteosarcoma-of-the-head-and-neck-in-adults
#18
Eline Boon, Winette T A van der Graaf, Hans Gelderblom, Margot E T Tesselaar, Robert J J van Es, Sjoukje F Oosting, Remco de Bree, Esther van Meerten, Ann Hoeben, Ludi E Smeele, Stefan M Willems, Max J H Witjes, Jan Buter, Robert J Baatenburg de Jong, Uta E Flucke, Petronella G M Peer, Judith V M G Bovée, Carla M L Van Herpen
BACKGROUND: There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck. METHODS: All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed. RESULTS: We identified a total of 77 patients with an osteosarcoma of the head and neck; the 5-year overall survival (OS) was 55%. In 50 patients with surgically resected high- or intermediate-grade osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, adjusting for age and resection margins, showed that patients who had not received chemotherapy had a significantly higher risk of local recurrence (hazard ratio [HR] = 3...
August 10, 2016: Head & Neck
https://www.readbyqxmd.com/read/27486986/mirna-193a-5p-repression-of-p73-controls-cisplatin-chemoresistance-in-primary-bone-tumors
#19
Camille Jacques, Lidia Rodriguez Calleja, Marc Baud'huin, Thibaut Quillard, Dominique Heymann, François Lamoureux, Benjamin Ory
Osteosarcoma and Ewing Sarcoma are the two most common types of Bone Sarcomas, principally localized at the long bones of the extremities and mainly affecting adolescents and young adults. Cisplatin is one of the current options in the therapeutic arsenal of drugs available to cure these aggressive cancers. Unfortunately, chemoresistance against this agent is still a major cause of patient relapse. Thus, a better understanding of the molecular pathways by which these drugs induce cancer cell death, together with a better delineation of the origins of chemoresistance are required to improve the success rate of current treatments...
July 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/27472771/here-there-and-nowhere-following-adult-survivors-of-childhood-cancer-a-case-report-of-recurrent-osteosarcoma-in-a-young-adult
#20
Suzanne McLaughlin, Christopher Terry, Fernando Barbosa, Bradley DeNardo
Approximately 1 in 285 children in the United States (US) will be diagnosed with cancer before the age of 20.1 More than 80% of children diagnosed with cancer will become long-term survivors.2 As of January, 2010, there are more than 380,000 adult survivors of childhood cancer in the US.3 More than two-thirds of survivors will develop chronic conditions.4 Professional organizations have advocated for specialized risk-based care of survivors.5 Locally and nationally, lack of transition services and insurance coverage are barriers to care of these adult survivors...
2016: Rhode Island Medical Journal
keyword
keyword
87669
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"